Boiron's Camilia(R) eases teething pains at Baby Show in Birmingham

Boiron will showcase Camilia®, a natural remedy for teething and related symptoms in babies and young children, at The Baby Show in Birmingham (UK) from 17 to 19 May 2013. Camilia® was launched on the British market on 1 May 2013 and is now available in a number of pharmacies. End Quote

(1888PressRelease) May 17, 2013 - Boiron launched Camilia®, a natural remedy for teething and related symptoms in babies and young children, in the UK on 1 May of this year. The company will showcase this remedy on Stand H10 at The Baby Show, the leading pregnancy and parenting event, to be held in Birmingham (England). The Baby Show is taking place from 17 to 19 May at the National Exhibition Centre (NEC).

Camilia® treats infant teething pains as well as related symptoms, such as crotchety behaviour, swollen gums, sore bottoms and profuse salivation. Thanks to its exclusive formula, which combines three natural substances - Chamomilla vulgaris 9c, Phytolacca decandra 5c and Rheum 5c - and purified water, Camilia® has been the remedy of choice for infants from Canada to Tunisia since it was first developed in the mid-1990s.

A liquid with a neutral taste, Camilia® contains no artificial colouring, no preservatives, no sugars, no lactose and no ethanol. The medication comes in sterile, drinkable single doses, which is ideal from the point of view of hygiene and makes it easy to administer to babies and toddlers.

Packaged in boxes of 10 single doses, Camilia® has a recommended retail price of £6.95 per box in the UK. The remedy can be bought over the counter (i.e. without mandatory medical prescription) from pharmacies and health food stores, as well as through many online-sales sites.

Teething generally occurs in children under the age of 2 ½ years, i.e. between three and 30 months. Teething is frequently accompanied by symptoms that are disagreeable for the infant and his (or her) family and carers, such as hyper-salivation, digestive troubles (linked themselves to a modification of the intestinal acidity, or pH), behavioural problems (including irritability and disturbed sleep), and associated ENT disorders (rhino-pharyngitis, etc.).

For Jérôme Delannoy, Export Director at Boiron, "The aim is that this medication should become a benchmark in Great Britain for all parents who are searching for a solution to treat easily, and without attendant side effects, their infants' teething pains."

About Boiron
Boiron was set up in 1932, when Jean and Henri Boiron, the company's founders, who were scientists and entrepreneurs at heart, launched the company.

In 2013, Boiron remains an independent, family-run laboratory - something of an exception in the international pharmaceuticals industry. Christian Boiron, son of Jean Boiron, is the company's Director-General.

The company's independence means that Boiron remains the master of its strategic choices. Boiron makes medications that are useful to public health and available to everyone - be they health professionals or the general public.

Today, the group is present in nearly 80 countries and continues the work of its founders, who were pioneers in the development of homeopathic medications worldwide.

In 2012, Boiron had a turnover of £488 million and employed 3,800 staff. The company is headquartered in Lyons (south-eastern France) and has a representative in London (UK).

Boiron will be on Stand H10 at The Baby Show, which is taking place at the NEC, in Birmingham (UK), from 17 to 19 May 2013.

For further information about the trade show, please go to: http://www.thebabyshow.co.uk/birmingham/

For further information about the company, please go to: http://www.boiron.com/

For further information, please contact :

Quote ref. : FTPB3854
Ms Katherine WOODS - Press Officer
UBIFRANCE Press Office in London
Tel: +44 (0) 207 024 3640
katherine.woods ( @ ) ubifrance dot fr
View other press releases at :
http://www.ubifrance.com/uk/

###

space

Other Related Press Releases